GlassScriptPhysician profile
Jehanzeb Qureshi
NPI 1871590836
$2,586.52
in general payments reported to CMS, 2019-2025
21 companies · $648 in 2025
The $648 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $142 · 2021: $182 · 2022: $333 · 2023: $355 · 2024: $542 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,545.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $701.41 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $421.65 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Novo Nordisk INC | $395.37 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $214.15 | 2019-2025 | |
| Abbott Laboratories | $177.20 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $162.96 | 2019-2025 | Eliquis |
| Abbvie INC. | $86.87 | 2021-2023 | |
| Daiichi Sankyo INC. | $59.18 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.36 | 2019-2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $48.90 | 2024-2025 | Arexvy |
| Janssen Pharmaceuticals, INC | $43.56 | 2019-2022 | |
| Exact Sciences Corporation | $36.70 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $35.49 | 2022 | |
| Cequr Corporation | $25.46 | 2024 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.29 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $23.53 | 2019 | |
| Amarin Pharma, INC. | $16.67 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.35 | 2022 | |
| Esperion Therapeutics, INC. | $15.27 | 2021 | |
| Currax Pharmaceuticals LLC | $14.55 | 2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $13.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jehanzeb Qureshi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.